The Surgery of the Hypertrophied Prostate

White, J William

doi:10.1097/00000658-189301000-00008

Cited by 8 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Later, in the nineteenth century, a number of reports describing a link between the testes and prostate gland were also published 6 . In 1893, the Philadelphia surgeon W. White measured changes in the size of the prostate gland in dogs after castration, reporting atrophy of glandular elements and a decrease in prostate weight 7 . He advocated castration as a treatment for urinary obstruction disorders.…”

Section: Androgen-ablation Therapymentioning

confidence: 99%

A history of prostate cancer treatment

2002

View full text Add to dashboard Cite

The increased incidence of prostate cancer has led to remarkable changes in diagnosis and treatment over the past century. What were the first ways in which prostate cancer was treated, and how did these evolve into the variety of therapeutic strategies from which patients have to choose today?In 1853, J. Adams, a surgeon at The London Hospital, described the first case of prostate cancer, which he discovered by histological examination 1 . Adams noted in his report that this condition was "a very rare disease". Remarkably, 150 years later, prostate cancer has become a significant health problem. In the United States, it is the most commonly diagnosed cancer in men, with 180,000 new cases and about 31,000 deaths occurring annually 2 . This dramatic increase in the number of prostate cancer cases can be attributed to several causes. First, prostate cancer was not differentiated from other types of urinary obstruction until the early 1900s. Second, the incidence of prostate cancer increases more rapidly with age than any other cancer type 2 . The number of cases has risen as the average life expectancy has increased over the past century. Third, the increased incidence seems to be, in some way, related to the 'Western' lifestyle: the incidence of clinical prostate cancer is significantly lower in Asian populations, compared with Western populations 3 , and it

show abstract

Section: Androgen-ablation Therapymentioning

confidence: 99%

A history of prostate cancer treatment

2002

View full text Add to dashboard Cite

show abstract

“…yüzyılın sonlarında W. White, köpeklerde, cerrahi kastrasyonla prostat hacminde değişimin üriner sistem obstruksiyonunun potansiyel tedavisi olduğunu yayınladı. [18] Bu hormonal tedavinin, prostat kanserinde etkin olabileceğinin ilk kanıtları idi. 1941 yılında ise, Huggins ve Hodges cerrahi (orşiektomi) ve medikal kastrasyon (östrojen enjeksiyonu) ile primer ve metastatik prostat kanserinde gerilemeyi göstererek, modern anti androjen tedavinin temelini oluşturmuştur.…”

Section: Androjen Deprivasyon Tedavisiunclassified

Hormonal therapy in advenced stage prostate cancer

Hacıbekiroğlu¹

2015

TJ Oncol

View full text Add to dashboard Cite

Prostat cancer is the most common type of cancer in men. At the time of diagnosis, only 5% of prostat cancer patients have the disease in advanced stage. While the 5 year overall survival rate of the patients with locoregional disease is close to 100%, this ratio in patients with advanced disease decreases to 28%. Prostat cancer cells depend on androgens for development, proliferation and physiological function. The purpose of the standard hormone therapy is to keep testesteron levels in castrate levels. Androgen deprivation therapy (ADT) is the standard treatment approach in prostat cancer patients with advanced stage. Although this treatment possesses many clinical benefits, it has also side effects affecting many systems in the body. This article evaluated the types and mechanisms of action of ADT, the management of this treatment's side effects, and the controversial situations commonly encountered in daily oncology practice in the light of current literature.Key words: Androgen deprivation therapy; prostate cancer.Prostat kanseri, erkeklerde en yaygın kanser türüdür. Prostat kanseri, tanı anında hastaların sadece %5'i ileri evre hastalığa sahiptir. Ancak hastalarda, 5 yıllık sağkalım, lokorejyonel hastalıkta %100'lerde iken, ileri evre hastalıkta bu oran %28'lere inmektedir. Prostat kanser hücreleri gelişme, proliferasyon ve fonksiyonları için androjenlere fizyolojik bağımlıdır. Standart hormon tedavisinin amacı ise testosteron düzeyini kastrasyon seviyelerinde tutmaktır. Androjen deprivasyon tedavisi (ADT), ileri evre prostat kanserinde standart tedavi yaklaşımıdır. ADT, klinik faydalarına ek olarak, vücuttaki birçok sistemi etkileyen yan etkilere sahiptir. Bu yazıda, ADT çeşitleri ve etkinlik mekanizmaları, günlük onkoloji pratiğinde sık karşılaşılan tartışmalı durumlar ve yan etki yönetimi güncel literatür bilgileri eşliğinde değer-lendirildi.

show abstract

“…In 1893, White [8], a surgeon from Philadelphia performed a series of experiments in which he mea- The good news * Presently, 85% of new cases are diagnosed at local and regional stages with 5-year relative survival rates of 100%. * The over death rate has been decreasing $4% per year since 1994.…”

Section: Developmentof Androgen-ablation Therapy For Prostate Cancermentioning

confidence: 99%

Development of prostate cancer treatment: The good news

Denmeade

Isaacs

2004

The Prostate

View full text Add to dashboard Cite

Prostate cancer is the most commonly diagnosed cancer in American men representing one-third of all new cancer cases each year. This translates into one out of every six American men being diagnosed with prostate cancer over the course of their lifetimes. Over 31,000 of these men die each year from prostate cancer. Before the 1980's, 50% of men were diagnosed with widespread metastatic disease and there were few therapeutic choices for patients. The good news for patients is that, over the last 30 years there have been significant advances in detection and prognostication as well as major improvements in the surgical, radiation, and medical oncological management of prostate cancer. This review describes the evolution of these therapeutic modalities for prostate cancer. This evolution has been driven by the explosion of knowledge concerning cancer in general and in the specific biology of prostate cancer in particular over the last 30 years. This knowledge has been obtained by concentrating human and financial resources in organ specific studies of the prostate. The end result of this effort is that, today, 85% of new prostate cancer cases are diagnosed at local and regional stages and the 5-year relative prostate cancer survival rate has increased by 20% since 1985. In addition, the therapeutic approach to prostate cancer can now be individualized based on the characteristics of the patient's disease. Finally, recent data suggest that the death rate from prostate cancer is decreasing by approximately 4% per year since 1994. Further good news for patients is that new discoveries about the biology of prostate cancer are rapidly being translated into new therapies, a large number of which are currently being tested in clinical trials. Continued allocation of appropriate human and material resources should yield new, more effective therapies for prostate cancer that will further impact patient quality of life and survival in the 21st century.

show abstract

The Surgery of the Hypertrophied Prostate

Cited by 8 publications

References 0 publications

A history of prostate cancer treatment

A history of prostate cancer treatment

Hormonal therapy in advenced stage prostate cancer

Development of prostate cancer treatment: The good news

Contact Info

Product

Resources

About